Evidence mapPaperPMID 41739359Full record

ReviewJournal of the Association for Research in Otolaryngology : JARO2026

Neural Hearing Loss: Mechanisms, Diagnosis and Treatment Horizons.

Eleni Genitsaridi, Efstratia Papoutselou, Cherith M Campbell-Bell, Leila Abbas, Rachel Haines, Douglas E H Hartley, Marcelo N Rivolta

Abstract readReview
In one paragraph

Review in Journal of the Association for Research in Otolaryngology : JARO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eleni Genitsaridi *Rinri Therapeutics Ltd., Sheffield, UK. eleni.genitsaridi@rinri-therapeutics.com.ORCID https://orcid.org/0000-0002-7752-4692
Efstratia Papoutselou *Rinri Therapeutics Ltd., Sheffield, UK. efstratia.papoutselou@rinri-therapeutics.com.ORCID http://orcid.org/0000-0002-1482-9501
Cherith M Campbell-BellRinri Therapeutics Ltd., Sheffield, UK.ORCID https://orcid.org/0000-0002-7094-6075
Leila AbbasRinri Therapeutics Ltd., Sheffield, UK.ORCID https://orcid.org/0009-0009-7013-5924
Rachel HainesRinri Therapeutics Ltd., Sheffield, UK.ORCID https://orcid.org/0000-0001-7924-0602
Douglas E H HartleyRinri Therapeutics Ltd., Sheffield, UK.ORCID https://orcid.org/0000-0001-9803-4169
Marcelo N RivoltaRinri Therapeutics Ltd., Sheffield, UK.ORCID https://orcid.org/0000-0003-4178-8570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neural hearing loss, characterized by dysfunction of the auditory nerve, including the spiral ganglion neurons (SGNs) and/or their synaptic connections, is increasingly recognized as a critical contributor to auditory deficits across diverse conditions, including Auditory Neuropathy Spectrum Disorder (ANSD), presbycusis, and noise-induced hearing loss (NIHL). It is possible that neural hearing loss is underdiagnosed, due to the lack of clinical tools with sufficient sensitivity and specificity to detect poor neural health. Current interventions, such as hearing aids and cochlear implants (CIs), primarily target sensory deficits and offer limited benefit in cases of significant neural compromise. Therapeutically, there is a growing shift towards biologically driven strategies aimed at restoring neural function. Recent developments in novel therapies, including pharmacological, gene-based, neurotrophic, and cell-based approaches, have opened new possibilities demonstrating the potential to protect, repair, and/or replace damaged SGNs, and re-establish auditory pathways. This perspectives article explores the evolving understanding of neural hearing loss, emphasizing its complex pathophysiology and the limitations of current diagnostic and therapeutic approaches, while highlighting how a diverse range of emerging solutions are moving closer to clinical application.

Indexed as

Hearing LossHearing Loss, CentralAnimalsHumansSpiral GanglionAuditory neural healthAuditory neuropathyCell therapyNeural hearing lossNeurodegenerationSpiral ganglion

Identifiers

PMID41739359
PMCPMC13090409

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.